Forbion Closes €2.3B 'Landmark' Fundraise for Biotech Push

Forbion has raised €2.3 billion in what the European venture firm itself calls a "landmark" fundraise, with the fresh capital earmarked to support 30 companies the firm describes as "high potential" biotechs.

The figure makes the raise one of the largest pools of dedicated life-sciences capital assembled by a European investment house in the current cycle. Forbion plans to deploy the money across roughly 30 portfolio companies working on new medicines, according to the firm's announcement reported by Fierce Biotech.

The size of the fund matters. It signals that institutional capital remains available for early- and growth-stage drug developers even after two difficult years for biotech financing, in which public listings slowed and many private companies struggled to extend their cash runways.

What does the €2.3B commitment mean for biotech?

For Forbion, the fundraise materially expands its capacity to write larger checks and to support companies through later, more expensive clinical stages. A pool of this scale allows the firm to back a pipeline of approximately 30 firms rather than scattering smaller amounts across a wider, shallower set of bets.

For the biotechs themselves, the implication is straightforward. A well-capitalized lead investor with dry powder reduces the risk that a promising program stalls between funding rounds — a scenario that has forced layoffs, pipeline cuts and fire-sale exits across the sector since 2022.

The "high potential" label attached to the target companies is the firm's own characterization. Forbion has built its franchise on therapeutic-area specialization, and its selection of roughly 30 names suggests a concentrated strategy rather than a broad index-style approach to the sector.

Why is a raise of this size notable now?

Biotech funding has been recovering unevenly. Large, headline-grabbing venture rounds have clustered around a small number of defensive platforms, while the broader middle of the market has faced tighter terms.

Against that backdrop, a €2.3 billion commitment stands out. It indicates that Forbion's limited partners — the pension funds, endowments and institutional investors that back such vehicles — are willing to make sizeable, long-duration allocations to drug development despite the sector's well-documented risks: high failure rates in clinical trials, long timelines to revenue and an unpredictable regulatory environment.

The firm's use of the word "landmark" for the close reflects both the absolute size of the pool and its timing. Capital raised now will be deployed over a multi-year investment window, meaning Forbion will be writing checks into market conditions that today's investors cannot fully predict.

Who benefits from the new fund?

The direct beneficiaries are the approximately 30 biotechs that Forbion has identified as "high potential" and intends to support with the new capital. For those companies, the fund represents access to a stable funding partner with the balance sheet to lead or join substantial rounds.

The indirect beneficiaries are the wider innovation ecosystem: academic spinouts, early-stage founders and co-investors who gain a well-funded anchor participant in European and cross-border biotech deals.

For patients and healthcare systems, the payoff is more distant. Venture capital ultimately finances the clinical trials that determine whether early-stage science becomes an approved therapy. A €2.3 billion pool directed at 30 drug developers increases the number of shots on goal.

What comes next?

Forbion will now move from fundraising to deployment. The pace of that deployment — which companies receive first allocations, at what valuations and in which therapeutic areas — will offer the market a real-time read on where one of Europe's best-capitalized life-sciences investors sees the strongest risk-adjusted returns. The firm's deal-making over the coming quarters will test whether the optimism embedded in a "landmark" €2.3 billion close translates into durable returns for its limited partners.